Trevena Inc (TRVN)

[ListenToMe]

This is the month for TRVN to Shine!!

[ListenToMe]

Lots of news anticipated for November and it is All Good!!

TRVN

[ListenToMe]

HUGE HUGE potential here for TRVN!!

[longboarder7892]

Have full position again with 100k shares picked them up yesterday and today close to the placement price. The back and fill was very bullish for the the mid term.Good luck to the longs.............

[GoodGuyBill]

Good point, HR. I too have a long term perspective on TRVN.

[HerbieRay]

These small biotechs with news only once in a while are very subject to shorting after their runups. If you believe in the company story, take a long term view. It's going to take them 2 or 3 quarters to develop any significant revenue and profit. I am looking out over 2 or 3 years and have been buying shares on a regular 2 week basis regardless of price.

[GoodGuyBill]

WTF...the pps is just falling, falling, falling...

[creakyhottie]

11 market makers each with the exact same amount on ask 22,800 shares each

something is fishy
'

[creakyhottie]

Announce Date11/2/2020
EPS Actual-$0.04
EPS SurpriseBeat by $0.01
Revenue Actual$3.00K
Revenue SurpriseMissed by -$1.50M

[creakyhottie]

loss of $.04

[HerbieRay]

Has TRVN published Q3 financials yet? I thought they were to be reporting on them Yesterday.

[ListenToMe]

https://www.trevena.com/pipeline : PIPELINE PAY ATTN.

TRVN PIPELINE PROGRESS....is something to watch closely... it will be one of the Major reasons TRVN will continue to climb!$$$



TRVN

[ListenToMe]

MAJOR Gains coming to TRVN.

Drug approval and Pipeline are huge indicators of a successful future!!

BIG MOVE COMING $$$$


TRVN

[ClayTrader]

* * $TRVN Video Chart 10-30-2020 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $TRVN Video Chart 10-29-2020 * *

Link to Video - click here to watch the technical chart video

[ListenToMe]

TRVN... preparing for a major move!

[HerbieRay]

Bought a bunch at the uptrend line. Hope it holds!

[$Pistol Pete$]

I hope so my Friend. Waiting patiently here

[nbm16yankees]

PP.. Thanks for your reply

In the interim, I went to the website and looked at the October presentation.

They think DEA approval will come in 4th qtr, (which is now) and Launch will take place in 1Q 21.

It was originally approved Aug 7, so I am guessing with 90 days from that. Just a guess.

[$Pistol Pete$]

I am not too sure about this

[nbm16yankees]

Any idea when we can expect the US DEA to assign it to its
schedule of controlled substances?

Do they assign it a date like FDA does with PDUFA?

Took this paragraph from their press release..

OLINVYK is a new chemical entity approved by the FDA in August 2020. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK will not be available for distribution until the United States Drug Enforcement Administration assigns it to its schedule of controlled substances. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at www.OLINVYK.com.

[HerbieRay]

I'm loving this consolidation part of the price. Buying shares on a 2 week regular basis regardless of price and looking out 2-3 years.

[murocman]

I love it even more at $2.90ish!

Beautiful cup & handle chart on the 3 month. Great setup to run hard on DEA approval and product launch!

GLTA,

Murocman

[ListenToMe]

...Have to Love TRVN @ $3.20.



TRVN

[longboarder7892]

Sitting here with over 60k shares from under 1.60 traded it a couple of times and locked in over 25k in trading profits. I told everyone that anything under 1.60 was a gift. Now Goldman is taking a stake. see you at $5.00. All the late buyers are welcomed too lol. Going golfing have a nice day

[$Pistol Pete$]

$TRVN Goldman Sachs Group Inc. Acquires New Stake in Trevena Inc (NASDAQ:TRVN)

https://www.tickerreport.com/banking-finance/6435438/goldman-sachs-group-inc-acquires-new-stake-in-trevena-inc-nasdaqtrvn.html

[$Pistol Pete$]

Agreed

[GoodGuyBill]

We're listening! To the moon!

[ListenToMe]

Beautiful TRVN Chart!!!

[ListenToMe]

Nice premkt action!
TRVN = HUGE Money!!!



.

[ListenToMe]

I'm calling TRVN to be Over $10.00 before end of year!

.BOOOOOMMM!!!

[longboarder7892]

a solid rally good volume looking for the move to $5.00

[ListenToMe]

Nice volume coming in. Price is going up... Very Bullish activity recently!!

TRVN = WINNING!!!



.

[ChillingPenguin]

I think if this drug becomes a blockbuster hit within the pain clinics, we can all take a trip to olive garden and enjoy a big bowl of pasta ?? yummy

[longboarder7892]

Slow and steady see you at 5.00$ plenty of time

[ListenToMe]

Trvn... BOOOOOMMMM

[ListenToMe]

027 = HUGE GAINS for TRVN$$$$$



TRVN

[ListenToMe]

TRVN = Breakthrough
Is inevitable!!

Super-Surge = BIG MONEY $$$$

TVRN

[ListenToMe]

TRVN held up very well in a weak market.


Trvn

[ListenToMe]

Yahoo Finance: Trevena's Shares March Higher, Can It Continue?
Yahoo Finance: Trevena's Shares March Higher, Can It Continue?.
https://finance.yahoo.com/news/trevenas-shares-march-higher-continue-131901545.html

[HerbieRay]

Well the 1 year (July/Aug 2021) price target is touted at $5-6. That s based on projected revenue ramp-up.

There is a lot of technical resistance around #3.10-#3.15 from early August selling that has to be overcome...gradually eaten away.

I;m looking forward to consolidating around these prices into December so I can get more $$$ to invest. After a couple of good quarterly financial reports, I expect this to take off for the target.

I have high hopes for the company, not just with their "O" drug, but for other drugs they have in early phase trials.

IF everything works out, we might get to $30-$50 in 2-3 years

[creakyhottie]

From Yahoo FinanceTrevena's Shares March Higher, Can It Continue?

Zacks Equity Research
Wed, September 30, 2020, 9:19 AM EDT
As of late, it has definitely been a great time to be an investor in Trevena, Inc. TRVN. The stock has moved higher by 66.5% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider TRVN’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as TRVN has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company.

[ListenToMe]

TRVN... Very solid company!

[mick]

YES $TRVN

[ListenToMe]

From $3 to $30... TRVN!!!



TRVN

[ListenToMe]

MAJOR BREAK-OUT ALERT!!!$$$


TRVN creeping UP before going PARABOLIC!!!$$$


TRVN

[ListenToMe]

Thats why TRVN will soon be 10X Higher!



TRVN

[GoodGuyBill]

Has anyone hear any updates about this:



https://www.genengnews.com/covid-19-candidates/trevena-trv027/

Candidate: TRV027

Type: AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19. TRV027’s mechanism of action is designed to selectively target the reparative pathway that improves lung function and promote anti-inflammatory effects.

Status: Trevena said August 24 that Imperial College London (ICL) has launched a proof-of-concept study for TRV027 in COVID-19 patients. Through an ongoing collaboration with ICL, the company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19. ICL is sponsoring and funding the study, with additional support through the British Heart Foundation Centre for Research Excellence Award.

The randomized, double-blind, placebo-controlled study will enroll approximately 60 hospitalized, non-ventilated patients aged 18 or older with a confirmed COVID-19 infection. The study’s primary objective is to assess whether TRV027 reduces abnormal clotting associated with COVID-19. The study will also evaluate the effect of TRV027 on lung function and other clinical outcomes. The company currently expects to report top-line data in the first quarter of 2021.

In April 2020, Trevena filed a provisional patent application with the U.S. Patent and Trademark Office covering the use of TRV027 to treat ARDS in COVID-19 patients.

COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

[ListenToMe]

All signals are Bullish for TRVN.

[ListenToMe]

Something Huge seems to be getting ready to happen here!

TRVN